Supplementary Figures 1 - 6 from Inhibiting Tankyrases Sensitizes KRAS-Mutant Cancer Cells to MEK Inhibitors via FGFR2 Feedback Signaling

PDF file - 660KB, Supplementary Figure S1. All RAS mutant cell lines have a higher sensitivity to the TNKSi/MEKi combination. Supplementary Figure S2. Validation of TNKSi/MEKi combination in KRAS mutant cancer cells. Supplementary Figure S3. Combinations with MEK inhibitor in the SW480 cell line. Supplementary Figure S4. TNKSi/MEKi combination leads to enhanced inhibition of AKT signaling activity. Supplementary Figure S5. TNKSi potentiates MEKi by releasing a feedback loop on FGFR2 signaling. Supplementary Figure S6. Consequences of combined inhibition of TNKS and MEK on FGFR2 and AKT signaling pathways in KRAS mutant cell lines.